| TUPEB11 | Cause of death among infants by HIV status in Zambia, 2020-2021 | Poster exhibition | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| TUPEB12 | Increased dolutegravir coverage is associated with increase in viral load coverage and suppression among children living with HIV in Togo | Poster exhibition | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| TUPEB13 | Use of second-generation INSTIs in the treatment of children and adolescents in Mexico. A real-life national experience | Poster exhibition | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| EPB0271 | Assessment of transmitted drug resistance mutations to doravirine (MK-1439) in Argentina | E-poster | ART resistance |
| EPB0272 | Prevalence and dynamics of drug resistance during dolutegravir-containing treatment in a pediatric population living with HIV-1 (IMPAACT P1093) | E-poster | ART resistance |
| EPB0273 | Assessment of prevalence, patterns, and risk factors of HIV drug resistance among pregnant women living with HIV in Tanzania | E-poster | ART resistance |
| EPB0274 | Subtype A1, D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Mbarara, Uganda | E-poster | ART resistance |
| EPB0275 | Interpretation of doravirine resistance by algorithm in antiretroviral-naïve people with HIV in Haiti | E-poster | ART resistance |
| EPB0276 | Pretreatment drug resistance and molecular epidemiology of HIV-1 across the Philippines | E-poster | ART resistance |
| LBEPB16 | HIV drug resistance profile in clients experiencing treatment failure after the transition to a dolutegravir-based, first-line antiretroviral treatment regimen in Mozambique | E-poster | ART resistance |